Skip to main content
Article thumbnail
Location of Repository

The development of a novel native prothrombin assay for the more efficient management of oral anticoagulation therapy

By Adrian Jose Sylvester

Abstract

Disturbances of the natural balance between pro-coagulant and anticoagulant systems, due to hereditary or acquired factors may result in haemorrhagic or thrombotic diseases. Currently the INR/ISI coagulation monitoring system, introduced in 1983 by the World Health Organisation (WHO), is that of choice for most anticoagulation management clinics. Patients undergoing anticoagulation therapy must regularly attend specialised outpatient clinics for the close monitoring and maintenance of their INR. The automated laboratory caters for rapid online simultaneous analysis of multiple blood samples, resulting in the calculation of a patient’s INR from the recorded prothrombin time. The insensitivity of the prothrombin time test has been well documented, requiring a reduction in the prothrombin concentration of 45 % prior to the materialisation of clinically significant prothrombin times. The project aims to employ three avenues of biotechnology to aid in the development of an immuno or molecular imprinted polymer (MIP) based anticoagulation assay. The project will utilise computational molecular modelling in an attempt to visualise the tertiary structure of human prothrombin, which will allow the rational selection of antigenic sites for molecular imprinting or antibody production. An aqueous, prothrombin-imprinted homo-polymer was grafted to the gold surface of a surface plasmon resonance biosensor (Biacore). The Biacore allowed the real time monitoring of imprinted polymer binding characteristics to i homogeneous protein solutions. As a direct comparison of two technologies, molecular imprinting and immuno technology, polyclonal antibodies showing specificity towards the same prothrombin antigen were immobilised onto Biacore chips. The imprinted polymer graft and polyclonal antibody based assays recognised homogeneous solutions of prothrombin at a concentration range of 0.01 nM to 14.2 nM and 0.01 nM to 0.5 nM respectively. A randomised preliminary clinical trial was initiated to compare the two assays’ ability to differentiate plasma samples with a variety of INR values. The results thus far show promise for the development of a new anticoagulation assay using molecularly imprinted polymer technology. The ultimate aim for this project is to develop a consistently more accurate point-of-care anticoagulation therapy monitoring kit, incorporating this new technology, which can replace or be used concomitantly with the INR/ISI system currently in use. This thesis raises more questions regarding the efficacy of oral anticoagulation therapy (OACT) and argues for and against the necessity of a novel OACT management assay

Publisher: Cranfield University at Silsoe
Year: 2004
OAI identifier: oai:dspace.lib.cranfield.ac.uk:1826/917
Provided by: Cranfield CERES

Suggested articles

Citations

  1. (2000). A doi
  2. (1997). A glucose sensing polymer. doi
  3. (1979). Antibodies specific for bovine abnormal (des-gamma-carboxy) prothrombin. doi
  4. (1999). Biomolecule immobilisation on electrode surfaces by entrapment or attachment to electrochemically polymerised films. A review. doi
  5. (2002). Biosensor for dengue virus detection: sensitive, rapid, and serotype specific. doi
  6. (2002). Biosensors for in vivo glucose measurement: can we cross the experimental stage. doi
  7. (1983). Characterisation of the complementary deoxyribonucleic acid and gene coding for human prothrombin. doi
  8. (1977). Conformational analysis. 130. MM2. A hydrocarbon force field utilising V1 and V2 torsional terms. doi
  9. (1951). Congenital SPCA deficiency: A hitherto unrecognized coagulation defect with haemorrhage rectified by serum and serum fractions. doi
  10. (1989). Degradation of extracellular matrix proteins by haemorrhagic metalloproteinases. doi
  11. (1979). Effects of clofibrate and warfarin alone and in combination on the deposition of vitamin K1.
  12. (1982). Electromagnetic Surface Modes,
  13. (2003). First human experiments with a novel non-invasive, non-optical continuous glucose monitoring system. doi
  14. (2000). Haematology: Blood Coagulation. doi
  15. (2000). Identification and purification of vitamin K-dependent proteins and peptides with monoclonal antibodies specific for gamma-carboxyglutamyl (Gla) residues. doi
  16. (1983). Immunoasays of human prothrombin species which correlate with functional coagulant activities.
  17. (2003). Immunoassay for the determination of morphine-3-glucuronide using a surface plasmon resonance-based biosensor. doi
  18. (1999). Initiation of Warfarin therapy: recommendations and clinical pearls.
  19. (1990). Interaction of metalloproteinases with human α2 macroglobulin. doi
  20. (1972). Mechanism of action of warfarin. Warfarin and the metabolism of vitamin K. doi
  21. (1973). Mechanism of warfarin resistance. Warfarin and the metabolism of Vitamin K1. doi
  22. (1978). Metal ion induced conformational transitions of prothrombin and prothrombin fragment 1. doi
  23. (1995). Mimics of the binding sites of opiod receptors obtained by molecular imprinting of enkephalin and morphine. doi
  24. (2001). Mimotypes of the nicotinic receptor binding site selected by a combinatorial peptide library. doi
  25. (1996). Molecular Imprinting:Synthesis of polymer particles with antibody-like binding characteristics for glucose oxidase. Biochemical and biophysical research communications, doi
  26. (1982). Molecular Mechanics, American Chemical Society, doi
  27. (1997). Molecular mechanisms of platelet adhesion and activation. doi
  28. (1997). Molecularly imprinted polymer of beta-cyclodextrin for the efficient recognition of cholesterol. doi
  29. (1995). Optimal oral anticoagulant therapy in patients with mechanical heart valves. doi
  30. (1999). Out of hospital coagulation monitoring and management.
  31. (1999). Preparation of receptor mimics using the technique of molecular imprinting.
  32. (1977). Primary structure of human prethrombin 2 and alpha-thrombin.
  33. (1995). Production of a new monoclonal antibody specific to human des-gamma-carboxyprothrombin in the presence of calcium ions. Application to the development of a sensitive ELISA-test. doi
  34. (2002). Rational design of a polymer specific for microcystin-LR using a computational approach. In Press, doi
  35. (1996). Recognition in molecularly imprinted polymer α2-adrenoceptor mimics. doi
  36. References Adrian Sylvester Andersson L I
  37. References Adrian Sylvester Baird
  38. References Adrian Sylvester Biggs R & Douglas A S
  39. References Adrian Sylvester Booth
  40. References Adrian Sylvester Clark Jr.L C & Lyons C
  41. References Adrian Sylvester Durick K & Negulescu P
  42. (1941). Studies of the haemorrhagic sweet clover disease. IV. The isolation and crystallisation of the haemorrhagic agent.
  43. (1997). SYBYL line notation (SLN): A versatile language for chemical structure representation. doi
  44. (2000). The BARC biosensor applied to the detection of biological warfare agents.
  45. (1998). The Biology of prothrombin. doi
  46. (1983). The clinical pathology of intravascular coagulation. doi
  47. (1977). The gamma-carboxy glutamic acid content of human and bovine prothrombin following warfarin treatment. doi
  48. (1997). The initial reactions of graphite and gold with blood. doi
  49. (2001). The oral anticoagulant saga: Past, present and future. doi
  50. (1996). Towards artificial antibodies prepared by molecular imprinting. doi
  51. (2001). Turner A P doi
  52. (1989). Validation of the General Purpose Tripos 5.2 Force Field. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.